Mogamulizumab | Anti-CCR4 | Therapeutic Monoclonal Antibody

Aliquoted from the original drug | Now available for research use

Aliquots of the reference drug Mogamulizumab are now available as research consumables.

Mogamulizumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.

Not looking for Mogamulizumab Reference drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Poteligeo® / Mogamulizumab Reference Product

Drug namePoteligeo®
INNMogamulizumab
API typeMogamulizumab is produced in Chinese hamster ovary cells by recombinant DNA technology.
Pharmacotherapeutic group
Antineoplastic and immunomodulating agents, monoclonal antibodies
ATC code
L01FX09
Target of antibody
CCR4, a G protein-coupled receptor for CC chemokines
General function
Short descriptionMogamulizumab is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Mogamulizumab is a defucosylated, humanised IgG1 kappa immunoglobulin that selectively binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs including the skin, resulting in depletion of the target cells. CCR4 is expressed on the surface of some cancer cells including T cell malignancies, such as MF and SS in which CCR4 expression is inherent.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)The pharmacokinetics (PK) of Mogamulizumab was evaluated in adult patients with T-cell leukaemia-lymphoma (ATL) and CTCL over a dose range of 0.01 to 1 mg/kg administered as multiple doses of Mogamulizumab every week or every 2 weeks, and included the recommended 1.0 mg/kg dose and regimen.
Original license holder
Kyowa Kirin Holdings B.V.
Bloemlaan 2
2132NP Hoofddorp
Netherlands
Marketing authorisation numbers
EU/1/18/1335/001
Marketing authorisation holder
Kyowa Kirin Holdings B.V.
Bloemlaan 2
2132NP Hoofddorp
Netherlands
Name of the manufacturer of the biological active substance
Kyowa Kirin Co., Ltd.
Takasaki Plant
100-1 Hagiwara-machi, Takasaki-shi,
Gunma, 370-0013
Japan
Name and address of the manufacturer(s) responsible for batch releaseallphamed PHARBIL Arzneimittel GmbH
Hildebrandstr. 10-12
37081 Göttingen
Germany
Max shelf life
3 years
Storage conditions
2°C – 8°C
List of excipients
Citric acid monohydrate
Glycine
Polysorbate 80
Sodium hydroxide (for pH adjustment)
Hydrochloric acid (for pH adjustment)
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting